GlassScriptPhysician profile
Karen E Mccutcheon
NPI 1881613610
$14,134.39
in general payments reported to CMS, 2019-2025
56 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,485 · 2020: $1,574 · 2021: $1,819 · 2022: $2,266 · 2023: $2,102 · 2024: $2,120 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,840 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,839.93 |
| Education | $149.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,854.84 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,787.21 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Novo Nordisk INC | $1,299.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $845.58 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $830.62 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $782.77 | 2019-2024 | Krystexxa, Otezla, Repatha |
| Astellas Pharma US INC | $531.41 | 2019-2024 | Myrbetriq, Veozah |
| Amarin Pharma, INC. | $492.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $428.08 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $419.47 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $352.24 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $313.61 | 2019-2025 | Xifaxan |
| Pfizer INC. | $273.34 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $270.15 | 2022-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $266.73 | 2023-2025 | Gemtesa |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Mccutcheon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.